Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00696384 · ClinicalTrials.gov registry record · Phase 3
A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension
A Phase 3 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 3
- Development phase
- 418
- Enrollment target
NCT00696384 is a Phase 3 study that has completed, run by Takeda. The registered enrollment target is 418 participants.
The verdict
NCT00696384, a Phase 3 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 418 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the long term safety and tolerability of azilsartan medoxomil, once daily (QD), in participants with Essential Hypertension.
Interventions
- DRUG Placebo
- DRUG Azilsartan medoxomil
- DRUG Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 418 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00696384
The ClinicalTrials.gov registry entry for NCT00696384 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 418 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00696384 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00696384 about?
NCT00696384 is a clinical study titled "A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension". The purpose of this study is to determine the long term safety and tolerability of azilsartan medoxomil, once daily (QD), in participants with Essential Hypertension.
What is the current status of trial NCT00696384?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 418 participants. The study started on 2007-06. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00696384?
The interventions under investigation include: Placebo (DRUG), Azilsartan medoxomil (DRUG), Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications. (DRUG).
Who is sponsoring clinical trial NCT00696384?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.